Neuralink is developing "Blindsight," a brain-computer interface designed to restore vision to the blind, including those born without sight, by stimulating the visual cortex directly. The device, which bypasses damaged eyes or optic nerves, has secured FDA Breakthrough Device status. Human clinical trials are targeted to begin by 2026, with the aim of offering initial, low-resolution vision.